drugset / Trial / NCT00250094
Clinical Benefit of Topoisomerase Downregulation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16) 1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
Timeline
- Start
- 2004-05
- Primary completion
- 2005-06
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 50 mg | Oral |
| Subject | Topotecan | Small molecule | 0.4 mg/m2 | Other |